The research group, « Heterobetaines », from Alcalá University in colaboration with the research group « Hipersensibility to medicines and inmmunitary innate response » form IDI La Paz, present a new generation of inhibitors of alfa tumoral necrosis factor (TNF-α) production, useful to prevent and / or treat inflamatory diseases.
The group is looking for technical cooperation or license agreements with pharmaceutical companies, research centers or diagnostic and treatment against inflammatory diseases research institutions.
New inhibitors of TNF-α production are useful to prevent and/ or treat inflammatory diseases such as rheumatoid arthritis, osteoarthritis, Crohn disease, ulcerative colitis, asthma,bronchitis, chronic obstructive pulmonary disease, psoriasis, allergic rhinitis, ankylosing spondylitis, Hidradenitis suppurative, dermatitis and any other state with TNF-α high levels.
This compounds are capable to inhibit TNF- alpha expression at transcriptional level in primary human monocytes, what suggests that the mechanism could be related with some transcription factor and could regulate also the expression of additional citokinins. The effect seems to be apart independent from p38 MAPK or c-jun activation. The preliminary data suggest that NF-κB activity could be affected.
Besides TNF-α, these compounds also regulate the low production of of IL-1β y de IL-6 in THP-1 cells stimulated with LPS. The response to additional inflammatory stimulus has been explored such as poly I:C (ssRNA analogous) and the results show that this compounds also inhibit the TNF-α production and IL-12 response to stimulation with poly I:C in dendritic human cells differentiated in vitro.
Since metabolic diseases are related to low degree´s inflammation, the action of those new inhibitors has been explored in mature human adipocytes produced in vitro from mesenchymal stem cells. The results show a lower regulation that depends on IL-6 production and leptin in human adipocytes stimulated with LPS.
In vivo studies in animal models, previous treated with low doses of this compounds, exhibit significantly lower TNF- alpha production when are subjected to powerful pro-inflammatory stimuli such us LPS. This result indicates that the compounds present anti-inflammatory effectivity when are administrated in vivo.
In relation to safety, long term treatment in mice with low doses of this compounds present absence of kidney, lung or liver toxicity.
Intellectual property status
Granted Patent
Patent number : P201331143 and P201430411
Current development status
Development phase
Desired business relationship
Patent licensing
Technical cooperation
Intellectual property status
Other forms of protection
Internation Patent Applicatiuon PCT/ES2014/070603
The Technology Transfer Office at Alcalá University serves as a liaison between the University and its socioeconomic environment in terms of research and innovation. It encorages collaboration between research groups from universities and companies/institutions, with the objective to promote and commercialize research results and scientific capabilities.
Some of the services offered by this office are specified in the following list:
- Promotion of R & D and improvement of the relationships with companies.
- Promote the participation in R & D projects applicants to public calls (regional, national and European).
- Advising, processing and monitoring of patents and other forms of industrial protection.
- Support in the negotiation of contracts and agreements for R&D&i
Create your free account to connect with Universidad de Alcalá-OTRI and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Universidad de Alcalá-OTRI
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
